Capecitabine
- Generic Name
- Capecitabine
- Brand Names
- Ecansya, Xeloda, Capecitabine Medac, Ecansya (previously Capecitabine Krka), Capecitabine Accord, Capecitabine Teva
- Drug Type
- Small Molecule
- Chemical Formula
- C15H22FN3O6
- CAS Number
- 154361-50-9
- Unique Ingredient Identifier
- 6804DJ8Z9U
- Background
Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, that is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.
- Indication
Capecitabine is indicated as treatment for a variety of cancer types. For colorectal cancer, capecitabine is indicated as a single agent or a component of a combination chemotherapy regiment for the adjuvant treatment of stage III colon cancer and treatment unresectable or metastatic colorectal cancer. It can also be used as a part of a combination chemother...
- Associated Conditions
- Advanced or Metastatic Breast Cancer, Carcinoma of Gallbladder, Cholangiocarcinoma, Hepatocellular Carcinoma, Locally Advanced Rectal Cancer (LARC), Metastatic Adenocarcinoma of the Gastroesophageal Junction, Metastatic Gastric Cancers, Metastatic Neuroendocrine Tumors, Pancreatic Adenocarcinoma, Pancreatic Cancer, Advanced or Metastatic, Platinum-resistant Epithelial Ovarian Cancer, Refractory Fallopian Tube Carcinoma, Stage III Colon Cancer, Unresectable or Metastatic Colorectal Cancer, Metastatic pancreatic endocrine carcinoma, Refractory peritoneal cancer, Refractory, metastatic Colorectal carcinoma, Unresectable, metastatic Esophageal Cancer, Unresectable, metastatic Gastric Cancer, Unresectable, metastatic Gastroesophageal Junction Cancer
- Associated Therapies
- Chemotherapy
First-line Treatment with RC48 Plus Sintilimab and S-1 in Advanced Gastric Cancer (RCTS2)
- First Posted Date
- 2024-12-12
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- Qilu Hospital of Shandong University
- Target Recruit Count
- 110
- Registration Number
- NCT06730373
- Locations
- 🇨🇳
The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
🇨🇳Binzhou Medical University Hospital, Binzhou, Shandong, China
🇨🇳Shengli Oilfield Central Hospital, Dongying, Shandong, China
Toripalimab Combined With Capecitabine as Postoperative Adjuvant Therapy for Patients With Resectable Advanced Extrahepatic Biliary Tract Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-12-05
- Last Posted Date
- 2024-12-05
- Target Recruit Count
- 110
- Registration Number
- NCT06717464
- Locations
- 🇨🇳
Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin, China
Different Methods of Capecitabine in Patients With Non-PCR After Neoadjuvant Therapy for TNBC
- First Posted Date
- 2024-11-22
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- Shu Wang
- Target Recruit Count
- 1166
- Registration Number
- NCT06700382
- Locations
- 🇨🇳
Peking University People's Hospital, Beijing, Beijing, China
Irinotecan Liposomes +5-FU/LV Versus Capecitabine in Patients of Recurrence After Resection of Resectable BTC
- Conditions
- Interventions
- First Posted Date
- 2024-11-21
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- Sir Run Run Shaw Hospital
- Target Recruit Count
- 76
- Registration Number
- NCT06699459
- Locations
- 🇨🇳
Fujian Provincial Hospital, Fuzhou, Fujian, China
🇨🇳The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China
🇨🇳Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China
Donafenib Combined With Capecitabine for Postoperative Adjuvant Therapy of Biliary Malignant Tumors With High-risk Recurrence Risk
- Conditions
- Interventions
- First Posted Date
- 2024-11-12
- Last Posted Date
- 2024-11-20
- Target Recruit Count
- 70
- Registration Number
- NCT06685289
Perioperative Therapies in Locally Advanced Unresectable Gastric Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-10-08
- Last Posted Date
- 2024-10-16
- Lead Sponsor
- Jeeyun Lee
- Target Recruit Count
- 50
- Registration Number
- NCT06630130
A Phase III Study of YL201 in Recurrent or Metastatic Nasopharyngeal Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2024-10-07
- Last Posted Date
- 2024-10-07
- Lead Sponsor
- MediLink Therapeutics (Suzhou) Co., Ltd.
- Target Recruit Count
- 400
- Registration Number
- NCT06629597
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
Adebrelimab Combined With Capecitabine for Adjuvant Therapy in Cholangiocarcinoma With High-risk Recurrence Post-surgery
- Conditions
- Interventions
- First Posted Date
- 2024-09-23
- Last Posted Date
- 2024-09-23
- Target Recruit Count
- 122
- Registration Number
- NCT06607276
Liposomal Irinotecan in Combination With Oxaliplatin and S-1 Versus Gemcitabine Combined With Capecitabine as Postoperative Adjuvant Therapy for Pancreatic Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-08-26
- Last Posted Date
- 2024-08-27
- Lead Sponsor
- CSPC Ouyi Pharmaceutical Co., Ltd.
- Target Recruit Count
- 408
- Registration Number
- NCT06571461
A Phase 2 Study of PCS6422 with Capecitabine in Patients with Advanced or Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-08-23
- Last Posted Date
- 2024-10-10
- Lead Sponsor
- Processa Pharmaceuticals
- Target Recruit Count
- 90
- Registration Number
- NCT06568692
- Locations
- 🇺🇸
Valkyrie Clinical Trials, Los Angeles, California, United States
🇺🇸Clinical Research Alliance, Westbury, New York, United States
🇺🇸Gabrail Cancer Center Research, Canton, Ohio, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.